TABLE OF CONTENTS
1 INTRODUCTION 31
1.1 OBJECTIVES OF THE STUDY 31
1.2 MARKET DEFINITION 31
1.3 OVERVIEW OF THE EUROPE HEREDITARY CANCER TESTING MARKET 31
1.4 CURRENCY AND PRICING 33
1.5 LIMITATIONS 33
1.6 MARKETS COVERED 34
2 MARKET SEGMENTATION 37
2.1 MARKETS COVERED 37
2.2 GEOGRAPHICAL SCOPE 38
2.3 YEARS CONSIDERED FOR THE STUDY 39
2.4 DBMR TRIPOD DATA VALIDATION MODEL 40
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 43
2.6 MULTIVARIATE MODELLING 44
2.7 MARKET END USER COVERAGE GRID 45
2.8 SOURCE LIFELINE CURVE 46
2.9 DBMR MARKET POSITION GRID 47
2.10 VENDOR SHARE ANALYSIS 49
2.11 SECONDARY SOURCES 50
2.12 ASSUMPTIONS 50
3 EXECUTIVE SUMMARY 51
4 PREMIUM INSIGHT 54
4.1 PESTEL ANALYSIS 55
4.2 PORTERS FIVE FORCES 56
5 EUROPE HEREDITARY CANCER TESTING MARKET: REGULATIONS 57
6 MARKET OVERVIEW 62
6.1 DRIVERS 64
6.1.1 RISING INCIDENCE OF HEREDITARY CANCER 64
6.1.2 INCREASE IN THE GERIATRIC POPULATION 64
6.1.3 RISING HEALTHCARE SPENDING 65
6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING 65
6.2 RESTRAINTS 66
6.2.1 HIGH COST OF HEREDITARY CANCER TESTING 66
6.2.2 LACK OF SKILLED PROFESSIONALS 67
6.3 OPPORTUNITIES 67
6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS 67
6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS 68
6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS 69
6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES 69
6.4 CHALLENGES 70
6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING 70
6.4.2 RISING COMPETITION AMONG MARKET PLAYERS 71
7 EUROPE HEREDITARY CANCER TESTING MARKET, BY TEST TYPE 72
7.1 OVERVIEW 73
7.2 MULTI PANEL TEST 76
7.3 SINGLE-SITE GENETIC TEST 76
8 EUROPE HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE 77
8.1 OVERVIEW 78
8.2 BIOPSY 81
8.2.1 NEEDLE BIOPSIES 81
8.2.2 ENDOSCOPIC BIOPSIES 81
8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY 82
8.2.4 LAPAROTOMY AND THORACOTOMY 82
8.2.5 OTHERS 82
8.3 IMAGING 82
8.3.1 MAGNETIC RESONANCE IMAGING (MRI) 83
8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN 83
8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 83
8.3.4 NUCLEAR SCAN 83
8.3.5 ULTRASOUND 83
8.3.6 X-RAYS 83
8.4 LAB TESTS 84
8.4.1 BLOOD 84
8.4.2 URINE 84
8.4.3 OTHERS 84
9 EUROPE HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY 85
9.1 OVERVIEW 86
9.2 POLYMERASE CHAIN REACTION (PCR) 89
9.3 SEQUENCING 89
9.4 MICRO ARRAY 90
10 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE 91
10.1 OVERVIEW 92
10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME 95
10.3 COWDEN SYNDROME 95
10.4 LYNCH SYNDROME 96
10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME 96
10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP) 97
10.7 LI-FRAUMENI SYNDROME 97
10.8 VON HIPPEL-LINDAU DISEASE 98
10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME 98
11 EUROPE HEREDITARY CANCER TESTING MARKET, BY END USER 99
11.1 OVERVIEW 100
11.2 HOSPITALS 103
11.3 CLINICS 103
11.4 DIAGNOSTIC CENTERS 104
11.5 RADIOLOGY CENTERS 104
11.6 LABORATORIES 105
11.7 OTHERS 105
12 EUROPE HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL 106
12.1 OVERVIEW 107
12.2 DIRECT TENDER 110
12.3 RETAIL SALES 110
13 EUROPE HEREDITARY CANCER TESTING MARKET, BY REGION 111
13.1 EUROPE 112
13.1.1 GERMANY 120
13.1.2 FRANCE 124
13.1.3 U.K. 128
13.1.4 RUSSIA 132
13.1.5 ITALY 136
13.1.6 SPAIN 140
13.1.7 TURKEY 144
13.1.8 NETHERLANDS 148
13.1.9 SWITZERLAND 152
13.1.10 BELGIUM 156
13.1.11 REST OF EUROPE 160
14 EUROPE HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE 161
14.1 COMPANY SHARE ANALYSIS: EUROPE 161
15 SWOT ANALYSIS 162
16 COMPANY PROFILE 163
16.1 ABBOTT 163
16.1.1 COMPANY SNAPSHOT 163
16.1.2 REVENUE ANALYSIS 163
16.1.3 COMPANY SHARE ANALYSIS 164
16.1.4 PRODUCT PORTFOLIO 164
16.1.5 RECENT DEVELOPMENTS 164
16.2 ILLUMINA, INC. (2021) 165
16.2.1 COMPANY SNAPSHOT 165
16.2.2 REVENUE ANALYSIS 165
16.2.3 COMPANY SHARE ANALYSIS 166
16.2.4 PRODUCT PORTFOLIO 166
16.2.5 RECENT DEVELOPMENTS 167
16.3 PERKINELMER INC. (2021) 168
16.3.1 COMPANY SNAPSHOT 168
16.3.2 REVENUE ANALYSIS 168
16.3.3 COMPANY SHARE ANALYSIS 169
16.3.4 PRODUCT PORTFOLIO 169
16.3.5 RECENT DEVELOPMENTS 169
16.4 LIFELABS GENETICS 170
16.4.1 COMPANY SNAPSHOT 170
16.4.2 COMPANY SHARE ANALYSIS 170
16.4.3 PRODUCT PORTFOLIO 171
16.4.4 RECENT DEVELOPMENTS 171
16.5 EUROFINS SCIENTIFIC (2021) 172
16.5.1 COMPANY SNAPSHOT 172
16.5.2 REVENUE ANALYSIS 172
16.5.3 COMPANY SHARE ANALYSIS 173
16.5.4 PRODUCT PORTFOLIO 173
16.5.5 RECENT DEVELOPMENT 173
16.6 AMBRY GENETICS 174
16.6.1 COMPANY SNAPSHOT 174
16.6.2 REVENUE ANALYSIS 174
16.6.3 PRODUCT PORTFOLIO 175
16.6.4 RECENT DEVELOPMENTS 175
16.7 BIOCARTIS 176
16.7.1 COMPANY SNAPSHOT 176
16.7.2 REVENUE ANALYSIS 176
16.7.3 PRODUCT PORTFOLIO 177
16.7.4 RECENT DEVELOPMENTS 177
16.8 BIO-HELIX 178
16.8.1 COMPANY SNAPSHOT 178
16.8.2 PRODUCT PORTFOLIO 178
16.8.3 RECENT DEVELOPMENTS 178
16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021) 179
16.9.1 COMPANY SNAPSHOT 179
16.9.2 REVENUE ANALYSIS 179
16.9.3 PRODUCT PORTFOLIO 180
16.9.4 RECENT DEVELOPMENT 180
16.10 CENTOGENE N.V. (2021) 181
16.10.1 COMPANY SNAPSHOT 181
16.10.2 REVENUE ANALYSIS 181
16.10.3 PRODUCT PORTFOLIO 182
16.10.4 RECENT DEVELOPMENT 182
16.11 CEPHEID 183
16.11.1 COMPANY SNAPSHOT 183
16.11.2 PRODUCT PORTFOLIO 183
16.11.3 RECENT DEVELOPMENT 183
16.12 FULGENT GENETICS 184
16.12.1 COMPANY SNAPSHOT 184
16.12.2 REVENUE ANALYSIS 184
16.12.3 PRODUCT PORTFOLIO 185
16.12.4 RECENT DEVELOPMENT 185
16.13 INVITAE CORPORATION 186
16.13.1 COMPANY SNAPSHOT 186
16.13.2 REVENUE ANALYSIS 186
16.13.3 PRODUCT PORTFOLIO 187
16.13.4 RECENT DEVELOPMENT 187
16.14 NATERA, INC. (2021) 188
16.14.1 COMPANY SNAPSHOT 188
16.14.2 REVENUE ANALYSIS 188
16.14.3 PRODUCT PORTFOLIO 189
16.14.4 RECENT DEVELOPMENTS 189
16.15 4BASECARE. 191
16.15.1 COMPANY SNAPSHOT 191
16.15.2 PRODUCT PORTFOLIO 191
16.15.3 RECENT DEVELOPMENTS 192
17 QUESTIONNAIRE 193
18 RELATED REPORTS 196

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.